Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2017-01-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于深圳证券交易所公司管理部关注函[2017]第8号的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Guangzhou Shengjing Investment Co., Ltd. to the Shenzhen Stock Exchange's Company Management Department regarding a letter of concern about Jiangsu Sihuan Bioengineering Co., Ltd. The content includes detailed allegations of related-party transactions, director and management misconduct, contract disputes, and requests for third-party audits. It references multiple legal and regulatory issues, audit reports, and corporate governance concerns. The document is not a financial report, earnings release, or a simple announcement but rather a comprehensive reply addressing regulatory inquiries and corporate governance issues. It does not contain financial statements or quarterly/annual financial data but focuses on legal, governance, and management accountability matters. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory and compliance documents that do not fit other specific categories.
2017-01-16 Chinese
北京市京银律师事务所关于深圳证券交易所《关于对江苏四环生物股份有限公司的关注函》所涉相关事项之核查意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion report issued by a law firm (Beijing Genland Law Firm) regarding a regulatory inquiry letter ('关注函') issued by the Shenzhen Stock Exchange to Jiangsu Sihuan Biological Co., Ltd. The document discusses legal compliance, shareholder proposals, and corporate governance issues related to the company. It is not a financial report, earnings release, or management presentation. It is a detailed legal review and verification related to regulatory and corporate governance matters, which fits best under the category of Legal Proceedings Report (LTR). The document length is 8369 characters, indicating it is a substantive report, not a brief announcement or certification. Therefore, the classification is Legal Proceedings Report (LTR) with high confidence.
2017-01-16 Chinese
有关股东临时提案的说明公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding shareholder proposals for an extraordinary general meeting (临时股东大会), explanations about shareholder relationships, operational issues of subsidiaries, and related legal and financial matters. It does not contain financial statements or comprehensive financial data typical of annual or interim reports. It also does not appear to be a short announcement of a report publication or a certification. The content focuses on shareholder proposals, company governance, and operational disclosures related to specific issues and legal matters. This fits best with the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2017-01-16 Chinese
关于2017年第一次临时股东大会增加临时提案暨召开2017年第一次临时股东大会补充通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2017 first extraordinary general meeting (临时股东大会) of the company 四环生物 (stock code 000518). It includes multiple proposed agenda items for shareholder voting, such as investigations into shareholder actions, lawsuits against board members, governance issues, and election of board members. The content is focused on the meeting's agenda, proposals, and procedural details for the shareholder meeting. There is no financial data, earnings information, or audit results presented. The document is not a report itself but a notice and detailed agenda for a shareholder meeting, which fits the category of AGM Information (AGM-R). The length and detail confirm it is not a brief announcement but materials related to the AGM.
2017-01-11 Chinese
2017年第二次临时董事会会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a company's board of directors meeting. It details the date and attendance of the meeting, the voting results, and the content of the resolution regarding a share swap transaction. There is no financial report, earnings data, or regulatory filing referenced. The document focuses on board decisions and changes related to company assets. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2017-01-09 Chinese
北京四环生物制药有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It is issued by a certified public accounting firm (立信会计师事务所) and includes detailed financial statements such as the balance sheet, income statement, and cash flow statement for the period ending September 30, 2016. The document contains the auditor's opinion on the financial statements, management's responsibility, and the auditor's responsibility, which are typical components of an audit report. The length of the document (15,000 characters) and the presence of detailed financial data confirm it is the actual audit report, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR).
2017-01-09 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.